Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial

Marso, Steven; Poulter, Neil; Nissen, Steven; Nauck, Michael; Zinman, Bernard; Daniels, Gilbert; Pocock, Stuart; Steinberg, William; Bergenstal, Richard; Mann, Johannes; Ravn, Lasse; Frandsen, Kirstine; Moses, Alan; Buse, John

doi:10.1016/j.ahj.2013.07.012

Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial

Copy For Citation

Marso S. P., Poulter N. R., Nissen S. E., Nauck M. A., Zinman B., Daniels G. H., ...More

AMERICAN HEART JOURNAL, vol.166, no.5, pp.823-835, 2013 (SCI-Expanded)

Publication Type: Article / Article
Volume: 166 Issue: 5
Publication Date: 2013
Doi Number: 10.1016/j.ahj.2013.07.012
Journal Name: AMERICAN HEART JOURNAL
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.823-835
Akdeniz University Affiliated: No

Abstract

Background Diabetes is a multisystem disorder associated with a nearly twofold excess risk for a broad range of adverse cardiovascular outcomes including coronary heart disease, stroke, and cardiovascular death. Liraglutide is a human glucagon-like peptide receptor analog approved for use in patients with type 2 diabetes mellitus (T2DM).